[Market In] Far Exceeding the Target Amount by 10 Times… 2.1 Trillion Won in “Lump-Sum Funds” Flows into NH INVESTMENT & SECURITIES Corporate Bonds
NH INVESTMENT & SECURITIES to Conduct Bookbuilding for 200 Billion Won in Corporate Bonds on the 8th
Buy Orders Totaling 2.19 Trillion Flood In for 2-, 3-, and 5-Year Bonds
Proven Success as All Tranches Achieve Negative (-) Interest Rates
[Edaily Marketin LEE GEON-EOM Reporter] NH INVESTMENT & SECURITIES(005940)The company successfully secured its target issuance amount by raising funds exceeding 10 times the target amount during the bookbuilding process for its corporate bonds. Exterior of NH INVESTMENT & SECURITIES. (Photo courtesy of NH INVESTMENT & SECURITIES) According to the financial investment industry on the 8th, NH INVESTMENT & SECURITIES received 2.19 trillion won in orders during the bookbuilding for its unsecured corporate bonds totaling 200 billion won. Shinhan Investment & Securities, SamsungSecurities, Hana Securities, and DaishinSecurities served as the lead underwriters for the bookbuilding.
By maturity, the 2-year bond, which aimed to raise 50 billion won, received 670 billion won in buy orders. The 3-year bond, targeting 120 billion won, attracted 1.18 trillion won, while the 5-year bond, seeking 30 billion won, drew 340 billion won.
With demand far exceeding the target amount, the issuance rates were set at favorable levels. The spread over the benchmark rate is estimated at minus (-) 6 basis points (1 bp = 0.01 percentage point) for the 2-year bond, minus (-) 6 basis points for the 3-year bond, and minus (-) 3 basis points for the 5-year bond.
Fluctuations in credit spreads serve as an indicator of investor sentiment and capital flows in the corporate bond market. “Credit Signal” provides an intuitive analysis of the market’s overall trends…
SCL Science(246960)is accelerating its new drug development efforts, spearheaded by vaccines for liver and ovarian cancer. With the goal of submitting an Investigational New Drug (IND) application nex…
“Batoclimab,” a treatment for autoimmune diseases developed by HANALL BIOPHARMA CO.,LTD(009420), has received new drug approval in China. This comes approximately nine years after the company licensed…
